Apogee (NASDAQ: APGE) director swaps options for cash in AbbVie deal

AbbVie (ABBV) presented 20 new IBD studies at UEG Week 2026, including long-term data for risankizumab and upadacitinib. Risankizumab showed 3-year remission rates of 54.0%-73.1% in UC. Upadacitinib maintained 4-year remission rates of 78.9%-86.6% in CD. Real-world data showed upadacitinib reduced hospitalizations and surgeries in IBD patients.

AbbVie presented 20 scientific abstracts at UEG Week 2026, highlighting long-term data for SKYRIZI and RINVOQ in treating inflammatory bowel disease (IBD). Key findings include sustained clinical and endoscopic remission rates for up to four years in Crohn's disease and ulcerative colitis. Additionally, real-world data showed positive outcomes for patients switching to upadacitinib. The company also shared new insights on risankizumab subcutaneous induction in Crohn's disease.

AbbVie presented interim results showing 70.2% of evaluable patients with moderate-to-severe Crohn's disease responded to upadacitinib within 12 weeks. Long-term data for risankizumab and upadacitinib in Crohn's and ulcerative colitis showed sustained clinical and endoscopic outcomes. New data on investigational therapy ABBV-466 was also presented at UEGW 2026.

AbbVie (ABBV) and Genmab reported positive Phase 3 trial results for epcoritamab plus R-CHOP in high-risk diffuse large B-cell lymphoma, showing a 51% reduction in disease progression or death risk. The data suggest potential for front-line treatment, supporting AbbVie's oncology ambitions and revenue diversification. Regulatory filings and approvals will be key next steps.

AbbVie presented phase 3 study data at the 2026 EADV Congress, showing Rinvoq (upadacitinib) demonstrated continued facial and body repigmentation in non-segmental vitiligo through week 76. The data also included week-28 findings from a phototherapy substudy, where Rinvoq combined with NB-UVB phototherapy showed higher repigmentation responses than Rinvoq alone. Rinvoq is approved in the EU for NSV treatment and is under FDA review in the US.

AbbVie's risankizumab (Skyrizi) showed higher clinical remission and endoscopic response rates at week 12 and 24 in Crohn's disease patients compared to placebo, per a phase 3 AFFIRM study. The drug demonstrated a similar safety profile to other indications, according to a presentation at the ACG Annual Scientific Meeting. The study enrolled 289 adults with moderate to severe Crohn's disease, with primary endpoints being clinical remission and endoscopic response at week 12.